Evolving China’s Regulatory System in Alignment with ICH

About the Author

Placeholder Person Graphic
Charles C. Tong, PhD
Executive Vice President and Head of the R&D
Suzhou Ribo Life Science Co., Ltd.
Charles C. Tong, PhD, is Executive Vice President and Head of the R&D Center at Suzhou Ribo Life Science and is engaged in oligonucleotide drug...
Placeholder Person Graphic
Zhengyu Wu
Regulatory Affairs Director
Novo Nordisk (China) Pharmaceuticals
Zhengyu “Zero” Wu is Regulatory Affairs Director at Novo Nordisk (China) Pharmaceuticals. With 16 years of experience in drug regulatory affairs, he has long been...
Yang Gao, PhD
Chief Strategy Officer
Shanghai Bioraylab Medicine
Yang Gao, PhD, is Chief Strategy Officer at Shanghai Bioraylab Medicine, fully responsible for the drug development, regulatory affairs, and portfolio and project management for...
Placeholder Person Graphic
Meng Yang, PhD
Technical Regulatory Policy China Lead
Roche
Meng Yang, PhD, is Technical Regulatory Policy China Lead at Roche. Meng joined Roche in October 2019 as Technical Regulatory Policy China Lead, responsible for...
Placeholder Person Graphic
Mingping Zhang
Vice President, Technical
PAREXEL Consulting
Mingping Zhang is Vice President (Technical) at Parexel Consulting since January 2023. Previously he served as Vice President of Portfolio and Strategy Management at Suzhou...